Abstract
To date, there has been no effective therapy against hormone-refractory prostate cancer (HRPC). This led us to evaluate the efficiency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM) and Cis-platin (CDDP) combination chemotherapy in patients with HRPC. ECT at a daily dose of 560mg was given intravenously in combination with IFM, 1.2 g/m2, on days 1 to 5, and CDDP, 70 mg/ m2, on day 1. This combination therapy was given every 3 to 4 weeks. Twenty-one patients with HRPC were enrolled in this trial. An objective response of more than 50% reduction in prostate -specific antigen was observed in nine out of eighteen patients (50%), and more than 50% reduction in bidimensionally measurable soft-tissue lesions was observed in two out of seven patients (29%). The median response duration of overall partial response cases was 40 weeks, while the median response duration of overall partial response plus stable cases was 30 weeks. The median survival duration of all cases was 47 weeks. Toxicity was modest and acceptable; nausea/vomiting (67%), alopecia (48%), anemia (76%), leukocytopenia (57%), thrombocytopenia (48%), renal dysfunction (24%) and liver dysfunction (19%) were noticed. Severe toxicity was observed in two cases, one case with myocardial infarction and one case with deep vein thrombosis. We conclude that the ECT, IFM and CDDP combination chemotherapy regimen can be highly recommended for the treatment of HRPC.
| Original language | English |
|---|---|
| Pages (from-to) | 236-241 |
| Number of pages | 6 |
| Journal | Nishinihon Journal of Urology |
| Volume | 64 |
| Issue number | 4 |
| Publication status | Published - 2002 |
Fingerprint
Keywords
- Cis-platin
- Estramustine phosphate
- Hormone-refractory prostate cancer
- Ifosfamide
ASJC Scopus subject areas
- Urology
Cite this
Combination chemotherapy with estramustine phosphate, ifosfamide and cis-platin in hormone-refractory prostate cancer. / Kaku, Haruki; Tsushima, Tomoyasu; Nasu, Yasutomo; Saika, Takashi; Arata, Ryoji; Shirasaki, Yoshinori; Kurose, Kyohei; Nakata, Tetsuya; Kumon, Hiromi; Ohashi, Teruhisa; Miyaji, Yoshiyuki.
In: Nishinihon Journal of Urology, Vol. 64, No. 4, 2002, p. 236-241.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combination chemotherapy with estramustine phosphate, ifosfamide and cis-platin in hormone-refractory prostate cancer
AU - Kaku, Haruki
AU - Tsushima, Tomoyasu
AU - Nasu, Yasutomo
AU - Saika, Takashi
AU - Arata, Ryoji
AU - Shirasaki, Yoshinori
AU - Kurose, Kyohei
AU - Nakata, Tetsuya
AU - Kumon, Hiromi
AU - Ohashi, Teruhisa
AU - Miyaji, Yoshiyuki
PY - 2002
Y1 - 2002
N2 - To date, there has been no effective therapy against hormone-refractory prostate cancer (HRPC). This led us to evaluate the efficiency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM) and Cis-platin (CDDP) combination chemotherapy in patients with HRPC. ECT at a daily dose of 560mg was given intravenously in combination with IFM, 1.2 g/m2, on days 1 to 5, and CDDP, 70 mg/ m2, on day 1. This combination therapy was given every 3 to 4 weeks. Twenty-one patients with HRPC were enrolled in this trial. An objective response of more than 50% reduction in prostate -specific antigen was observed in nine out of eighteen patients (50%), and more than 50% reduction in bidimensionally measurable soft-tissue lesions was observed in two out of seven patients (29%). The median response duration of overall partial response cases was 40 weeks, while the median response duration of overall partial response plus stable cases was 30 weeks. The median survival duration of all cases was 47 weeks. Toxicity was modest and acceptable; nausea/vomiting (67%), alopecia (48%), anemia (76%), leukocytopenia (57%), thrombocytopenia (48%), renal dysfunction (24%) and liver dysfunction (19%) were noticed. Severe toxicity was observed in two cases, one case with myocardial infarction and one case with deep vein thrombosis. We conclude that the ECT, IFM and CDDP combination chemotherapy regimen can be highly recommended for the treatment of HRPC.
AB - To date, there has been no effective therapy against hormone-refractory prostate cancer (HRPC). This led us to evaluate the efficiency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM) and Cis-platin (CDDP) combination chemotherapy in patients with HRPC. ECT at a daily dose of 560mg was given intravenously in combination with IFM, 1.2 g/m2, on days 1 to 5, and CDDP, 70 mg/ m2, on day 1. This combination therapy was given every 3 to 4 weeks. Twenty-one patients with HRPC were enrolled in this trial. An objective response of more than 50% reduction in prostate -specific antigen was observed in nine out of eighteen patients (50%), and more than 50% reduction in bidimensionally measurable soft-tissue lesions was observed in two out of seven patients (29%). The median response duration of overall partial response cases was 40 weeks, while the median response duration of overall partial response plus stable cases was 30 weeks. The median survival duration of all cases was 47 weeks. Toxicity was modest and acceptable; nausea/vomiting (67%), alopecia (48%), anemia (76%), leukocytopenia (57%), thrombocytopenia (48%), renal dysfunction (24%) and liver dysfunction (19%) were noticed. Severe toxicity was observed in two cases, one case with myocardial infarction and one case with deep vein thrombosis. We conclude that the ECT, IFM and CDDP combination chemotherapy regimen can be highly recommended for the treatment of HRPC.
KW - Cis-platin
KW - Estramustine phosphate
KW - Hormone-refractory prostate cancer
KW - Ifosfamide
UR - http://www.scopus.com/inward/record.url?scp=0036247383&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036247383&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0036247383
VL - 64
SP - 236
EP - 241
JO - Nishinihon Journal of Urology
JF - Nishinihon Journal of Urology
SN - 0029-0726
IS - 4
ER -